Copyright © 2018 ALM Media Properties, LLC. All Rights Reserved.
On June 14, a unanimous Supreme Court decision in Ass'n for Mol. Pathology v. Myriad Genetics, Inc., held that Myriad's claims directed to "… a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated." 569 U.S. ___ (2013), Slip Op. at 18. In addition, the court held that "… cDNA is patent eligible because it is not naturally occurring."
To view this content, please continue to Lexis Advance®.
Not a Lexis Advance® Subscriber? Subscribe Now
LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via Lexis Advance®. This includes content from the National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.
ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.
For questions call 1-877-256-2472 or contact us at firstname.lastname@example.org